RxDoctor Payments Data

Lauren Kessenich

Family · Jacksonville, FLNPI 1952830093

Payments from drug & device makers

$10,994in general payments, 2019–2025

Across 596 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$735
  • QOL Medical, LLC$659
  • Regeneron Healthcare Solutions, Inc.$529
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$10,988100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,994 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$80,672
Medicare patients
512
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$359,343
CreonLipase/Protease/Amylase44$165,613
LinzessLinaclotide28$30,121
Mesalamine16$7,594
Dexlansoprazole DrDexlansoprazole17$4,220
Omeprazole210$3,454
Famotidine120$2,193
Colestipol Hcl22$2,109
Pantoprazole Sodium122$1,879
Esomeprazole Magnesium27$1,474
Sucralfate44$1,193
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine29$924
Amitriptyline Hcl37$806
Metoclopramide Hcl20$546
Ondansetron OdtOndansetron30$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,151$359,34314 claims
AbbVieCreon, Linzess$2,906$195,73472 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →